Italia markets open in 1 hour 2 minutes

Olema Pharmaceuticals, Inc. (OLMA)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
9,84-1,01 (-9,31%)
Alla chiusura: 04:00PM EDT
10,15 +0,31 (+3,15%)
Dopo ore: 06:29PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente10,85
Aperto11,35
Denaro9,81 x 200
Lettera9,85 x 100
Min-Max giorno9,70 - 11,40
Intervallo di 52 settimane5,02 - 17,79
Volume1.168.791
Media Volume819.116
Capitalizzazione550,389M
Beta (5 anni mensile)2,10
Rapporto PE (ttm)N/D
EPS (ttm)-2,00
Prossima data utili06 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A24,88
  • GlobeNewswire

    Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

    Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor conference call at 8:00 a.m. ET on October 23, 2023 SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced an oral presen

  • GlobeNewswire

    Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

    Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced new preclinical data regarding the discovery of novel compounds targeting KAT6, an epig

  • GlobeNewswire

    Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

    Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approximately 60 patients Expanded study supports the potential late-stage development of palazestrant in first-line advanced or metastatic breast cancer in combination with ribociclib SAN FRANCISCO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the